<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324346</url>
  </required_header>
  <id_info>
    <org_study_id>RKH2014.1</org_study_id>
    <nct_id>NCT04324346</nct_id>
  </id_info>
  <brief_title>Central Catheters Used for Chemotherapy in Women With Breast Cancer</brief_title>
  <acronym>PICC&amp;PAC</acronym>
  <official_title>Evaluation of Central Venous Catheters Used for Chemotherapy in Women With Breast Cancer - An Interdisciplinary Randomized Controlled Study of Complications, Material Wear, Staff- and Patient Perspectives, and Health Economy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Red Cross University College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KTH Royal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stockholm South General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Red Cross University College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this study is to evaluate two different central venous lines, PICC-lines
      (PICC) and subcutaneous venous access ports (SVAP) used for chemotherapy in women with breast
      cancer. The study will compare complications, material wear of the catheters used, patients'-
      and health care professionals' experiences, and costs. The study will give knowledge about
      which central venous access that is the most advantageous regarding adjuvant chemotherapy for
      women with breast cancer in the aspects of safety, quality of care, and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N=250 women between 18 and 70 years of age with invasive breast cancer who are allocated to
      adjuvant or neo adjuvant chemotherapy during 18 weeks at the Department of Oncology at
      Karolinska University Hospital , Stockholm Sweden are eligible to participate in the present
      study. Exclusion criteria are cognitive dysfunction and/or inability to understand Swedish.
      Before participation an informed consent will be collected. The patients will be randomized
      to receive a PICC or a SVAP. Complications will be registered as well as the treatments.

      Bacterial cultures will be taken at removal of PICC/SVAP. The used PICC/SVAP will be
      transported to the Royal Institute of Technology (KTH) and subjected to material analyses.
      Comparison with reference materials from the in-vitro study and with new reference catheters
      will be performed. Patient assessments with questionnaire concerning HRQL, illness
      perception, body imaging, life style and sleep disturbance will be collected at baseline and
      at the last chemotherapy session. Interviews with the patients about life situations will be
      conducted half through the chemotherapy treatment period.In- and out-patients costs, i.e.
      medication, materials, costs related to the care of the PICC/SVAP, costs for complications,
      additional costs for the patients regarding the treatment, etc., will be monitored and
      registered. In- and out-patient costs will also be monitored. Data from medical records
      concerning treatments for complications will also be taken into consideration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complications</measure>
    <time_frame>Through study completion up to 18 weeks</time_frame>
    <description>all complications during the chemotherapy treatment period are registered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire EQ-5D</measure>
    <time_frame>At baseline, at 9 weeks and at end of treatment period 18 weeks (3 measurements)</time_frame>
    <description>Health related quality of life is measured with scores and a scale using EQ-5D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire EORT-QLQ 30</measure>
    <time_frame>At baseline, at 9 weeks and at end of treatment period 18 weeks (3 measurements)</time_frame>
    <description>To measure Health related quality of life for patients with cancer the questionnaire EORT-QLQ 30 (Scores) is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire EORT-QLQ BR32</measure>
    <time_frame>At baseline, at 9 weeks and at end of treatment period 18 weeks (3 measurements)</time_frame>
    <description>The Questionnaire EORT-QLQ BR32 (Scores) is used to measure Health related quality of life for patients with breast cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire Insomnia Symptom Score</measure>
    <time_frame>At baseline, at 9 weeks and at end of treatment period 18 weeks (3 measurements)</time_frame>
    <description>To measure Sleep disturbance the questionnaire Insomnia Symptom Score (Scores) is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Esteem Scale (BES)</measure>
    <time_frame>At baseline, at 9 weeks and at end of treatment period 18 weeks (3 measurements)</time_frame>
    <description>The participants Body image is measured by Questionnaire: Body Esteem Scale (BES) (Scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enriched Social Support Instrument (ESSI)</measure>
    <time_frame>At baseline, at 9 weeks and at end of treatment period 18 weeks (3 measurements)</time_frame>
    <description>The participants social support is measured with the questionnaire: Enriched Social Support Instrument (ESSI) (Scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief-Illness Perception Questionnaire (B-IPQ)</measure>
    <time_frame>At baseline, at 9 weeks and at end of treatment period 18 weeks (3 measurements)</time_frame>
    <description>Illness Perception is measured with the questionnaire: Brief-Illness Perception Questionnaire (B-IPQ) (scores)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Morphological material degradation</measure>
    <time_frame>After study completion up to 18 weeks</time_frame>
    <description>Morphological surface changes of PICC and SVAP after clinical use.
End-ponits:
• Material degradation of PICC/SVAP measured with Scanning Electronic Microscopy</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economy related to HRQL</measure>
    <time_frame>At baseline, 9 weeks and at study completion 18 weeks (3 measurements)</time_frame>
    <description>Questionnaire EQ-5D (scores transformed to Qaly) In- and out-patient costs for PICC/SVAP</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economy related to PICC and SVAP</measure>
    <time_frame>Retrospective data assessment after study completion 18 weeks</time_frame>
    <description>Device costs, maintenance costs (including complication cost), operation costs, staff costs retrieved from medical and economical records</description>
  </other_outcome>
  <other_outcome>
    <measure>Lived experience of complications</measure>
    <time_frame>weekly, through study completion up to 18 weeks</time_frame>
    <description>Structured diary filled by the participants regarding VAS, Visual Analog Scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Lived experience of management of complications</measure>
    <time_frame>weekly, through study completion up to 18 weeks</time_frame>
    <description>Structured study specific diary filled by the participants regarding time management of device and complications.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Catheter Related Complications</condition>
  <arm_group>
    <arm_group_label>PICC-Line</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women allocated to PICC-line when receiving chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Venous Access Port (SVAP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women allocated to SVAP when receiving chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC75 (or EC90) x 6</intervention_name>
    <description>Type of Chemotherapy</description>
    <arm_group_label>PICC-Line</arm_group_label>
    <arm_group_label>Subcutaneous Venous Access Port (SVAP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC100 + Taxotere (EC90 + Taxotere) 3+3</intervention_name>
    <description>Type of Chemotherapy</description>
    <arm_group_label>PICC-Line</arm_group_label>
    <arm_group_label>Subcutaneous Venous Access Port (SVAP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Type of Chemotherapy</description>
    <arm_group_label>PICC-Line</arm_group_label>
    <arm_group_label>Subcutaneous Venous Access Port (SVAP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adjuvant or neo adjuvant chemotherapy,

          -  speak Swedish

        Exclusion Criteria:

          -  cognitive dysfunction

          -  and/or inability to understand Swedish,

          -  recurrent breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunilla Björling, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Swedish Red Cross University College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gunilla Björling, PhD</last_name>
    <phone>+46858751673</phone>
    <email>bjog@rkh.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Onkologiska kliniken, Karolinska University Hospital, Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunilla Björling, PhD</last_name>
      <phone>+46858751673</phone>
      <email>gunilla.bjorling@rkh.se</email>
    </contact>
    <contact_backup>
      <last_name>Sara Stridh, PhD</last_name>
      <email>sara.stridh@rkh.se</email>
    </contact_backup>
    <investigator>
      <last_name>Annelie Liljegren, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fredrik Saboonchi, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ragnhild E Aune, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claes Frostell, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Stridh, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanna Albert, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swedish Red Cross University College</investigator_affiliation>
    <investigator_full_name>Gunilla Bjorling</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>picc-line</keyword>
  <keyword>central venous access port</keyword>
  <keyword>catheter related complications</keyword>
  <keyword>Infections</keyword>
  <keyword>thrombosis</keyword>
  <keyword>Material degradation</keyword>
  <keyword>Health economic costs</keyword>
  <keyword>Bio-material</keyword>
  <keyword>Health related quality of life</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be available 9 months after study completion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

